Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 11, Status: Authorised
Keyword(s):
Keyword(s):